Fig. 7
The expression profiles and correlation with prognosis of the EZH2/miR-139-5p/TOP2A axis in HCC. (A) The heatmap shows the expression profiles of EZH2 and TOP2A across tumor samples and paired normal tissues in 31 tumors in the TCGA database. E-N for EZH2 expression in normal tissues, E-T for EZH2 expression in tumor tissues, T-N for TOP2A expression in normal tissues, T-T for TOP2A expression in tumor tissues. (B) The expression of EZH2 and TOP2A in HCC cohorts (GSE14520 and GSE6764). (C) Protein levels of EZH2 and TOP2A in ten pairs of HCC tissues and para-carcinoma tissues. (D) mRNA levels of EZH2, TOP2A and miR-139-5p in ten pairs of HCC tissues and para-carcinoma tissues. (E) The expression of miR-139-5p in HCC in the TCGA database. (F) The expression correlation of EZH2, TOP2A and miR-139-5p in ten pairs of HCC tissues and para-carcinoma tissues. (G) Overall survival rate of HCC from the TCGA database analyzed according to the mRNA levels of EZH2 and TOP2A. HCC patients were divided into high and low groups according to the median mRNA expression level of EZH2 and TOP2A, respectively. HH for EZH2-High/TOP2A-High (n = 158); EZH2-High/TOP2A-Low (n = 27); EZH2-Low/TOP2A-High (n = 27); LL for EZH2-Low/TOP2A-Low (n = 158). (H) The correlation of EZH2, TOP2A, and miR-139-5p with overall survival (OS), relapse-free survival (RFS), progression-free survival (PFS), and disease-free survival (DFS) in patients with HCC. *p < 0.05, **p < 0.01, ***p < 0.001